Eder Anne F, Mitchell Tanya, Dy Beth, Herron Ross M, Ellen Wissel Mary, Lightfoot Thomas, Jo Drew Mary, Mair David
American Red Cross, Biomedical Services, National Headquarters, Washington, DC, USA.
J Clin Apher. 2011;26(3):116-22. doi: 10.1002/jca.20279. Epub 2011 Jan 25.
We conducted a donor survey to assess the occurrence of facial flushing and other symptoms during automated 2-U red cell collections (2RBC) and plateletpheresis (PLT) procedures and evaluated the possible association of the reactions with angiotensin-converting enzyme (ACE) inhibitors or with the collection technology.
An online survey was developed using Zoomerang to capture details of the donors' experience and medication use after 2RBC or PLT donations in regional blood centers of the American Red Cross.
Between 12/16/09 and 4/19/10, 1,299 donors in five American Red Cross blood center regions completed an online survey (739 2RBC, 4.2% total registrations; 560 PLT, 2.3% total registrations). Facial flushing was reported by 29 donors, and was more likely associated with 2RBC than PLT procedures (3.0% vs. 1.3%, P = 0.03). Facial flushing with 2RBC donation was reported by eight of 72 (11%) donors on ACE inhibitors; and 14 of 667 (2%) donors who were not taking ACE inhibitors (P = 0.001). The incidence of facial flushing reactions with PLT donation was less than 2% whether donors reported ACEI inhibitor use or not. More than 95% of the donors reported their intent to donate again, regardless of symptoms.
Facial flushing was more often reported by 2RBC donors taking ACE inhibitors than other donors [11% vs. 2%; P = 0.001]; and was uncommon among PLT donors, irrespective of ACE inhibitor use (<2%). All blood donors should be informed of the potential for common, minor side effects of the collection procedure and the possible but rare occurrence of more medically serious complications.
我们进行了一项献血者调查，以评估在自动采集2单位红细胞（2RBC）和血小板单采（PLT）过程中面部潮红及其他症状的发生情况，并评估这些反应与血管紧张素转换酶（ACE）抑制剂或采集技术之间的可能关联。
使用Zoomerang开发了一项在线调查，以获取美国红十字会地区血液中心2RBC或PLT献血后献血者的经历及用药情况的详细信息。
在2009年12月16日至2010年4月19日期间，美国红十字会五个血液中心地区的1299名献血者完成了在线调查（739例2RBC，占总登记人数的4.2%；560例PLT，占总登记人数的2.3%）。29名献血者报告有面部潮红，且2RBC采集过程比PLT采集过程更易出现面部潮红（3.0%对1.3%，P = 0.03）。72名服用ACE抑制剂的2RBC献血者中有8名（11%）报告面部潮红；667名未服用ACE抑制剂的献血者中有14名（2%）报告面部潮红（P = 0.001）。无论献血者是否报告使用ACEI抑制剂，PLT献血时面部潮红反应的发生率均低于2%。超过95%的献血者表示无论有无症状都打算再次献血。
服用ACE抑制剂的2RBC献血者比其他献血者更常报告面部潮红[11%对2%；P = 0.001]；PLT献血者中面部潮红不常见，无论是否使用ACE抑制剂（<2%）。应告知所有献血者采集过程可能出现常见、轻微副作用以及更严重医学并发症可能但罕见的发生情况。
